BioCentury
ARTICLE | Clinical News

Amrubicin misses in lung cancer

May 20, 2011 12:41 AM UTC

Second-line treatment with amrubicin from Celgene Corp. (NASDAQ:CELG) missed the primary endpoint of significantly improving overall survival vs. topotecan in the Phase III ACT-1 trial to treat small ...